Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Cash from Operations (2023 - 2025)

Historic Cash from Operations for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to -$52.9 million.

  • Nuvation Bio's Cash from Operations fell 7016.25% to -$52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$190.0 million, marking a year-over-year decrease of 9165.02%. This contributed to the annual value of -$130.4 million for FY2024, which is 9178.66% down from last year.
  • According to the latest figures from Q3 2025, Nuvation Bio's Cash from Operations is -$52.9 million, which was down 7016.25% from -$48.2 million recorded in Q2 2025.
  • Over the past 5 years, Nuvation Bio's Cash from Operations peaked at -$15.0 million during Q4 2023, and registered a low of -$52.9 million during Q3 2025.
  • Its 3-year average for Cash from Operations is -$31.1 million, with a median of -$31.1 million in 2024.
  • The largest annual percentage gain for Nuvation Bio's Cash from Operations in the last 5 years was 1876.88% (2024), contrasted with its biggest fall of 20808.44% (2024).
  • Nuvation Bio's Cash from Operations (Quarter) stood at -$15.0 million in 2023, then tumbled by 208.08% to -$46.3 million in 2024, then fell by 14.24% to -$52.9 million in 2025.
  • Its last three reported values are -$52.9 million in Q3 2025, -$48.2 million for Q2 2025, and -$42.6 million during Q1 2025.